Virtual Symposium - Assessing the Evolving Role of GLP1-RAs to Reduce Cardiovascular Risk: Emerging Evidence, Evolving Guidance, and Expert Perspectives
GLP-1 RAs have carved an important role in the management of patients with type 2 diabetes (T2D), not only in glycemic control, but also in reducing cardiovascular and renal risk.
Category
  • CMHC
Format
  • Video
Credits
  • 1.00 ABIM MOC and AMA PRA Category 1 Credit™
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 CDE
  • 1.00 Participation
The Disproportionate Burden of Heart Failure in Women: Advances & Expert Perspectives to Improve Diagnosis & Treatment
The prevalence of heart failure (HF) is greater in women compared to men; however, significant gaps exist in the management of women with this condition.
Category
  • CMHC
Format
  • Self-study / Enduring
Credits
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
Virtual Symposium - Escaping the Current Gaps in the Understanding and Treatment of CKD Anemia: Making Sense of Emerging Therapies
Anemia is a common comorbidity in patients with chronic kidney disease (CKD), and is associated with significant morbidity and impacts on quality of life.  The complicated pathophysiology of the condition and the disadvantages associated with current treatments are some of the major barriers that
Category
  • CMHC
Format
  • Video
Credits
  • 1.00 ABIM MOC and AMA PRA Category 1 Credit™
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 CDE
  • 1.00 Participation
Making Sense of LDL-C Combination Therapy in 2022: Strategies and Pearls to Move Beyond Inertia to Improve Patient Outcomes
Lowering LDL-C effectively and safely is paramount to prevent and lower the risk of recurrent ASCVD events.  Even with the advances in LDL-C lowering therapy, LDL-C goal achievement is low, and clinical inertia and patient non-adherence are major factors for continued ASCVD residual risk.  The la
Category
  • CMHC
Format
  • Self-study / Enduring
Credits
  • 1.25 ABIM MOC and AMA PRA Category 1 Credit™
  • 1.25 ACPE Pharmacy
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC
  • 1.25 CDE
  • 1.25 Participation
Navigating the Diagnosis and Treatment of Patients with Narcolepsy and Cardiovascular Risk
Several cardiometabolic comorbidities are common in patients with narcolepsy.  Often these disorders are overlooked, but they have important implications in the management of this condition.
Category
  • CMHC
Format
  • Self-study / Enduring
Credits
  • 1.50 ABIM MOC and AMA PRA Category 1 Credit™
  • 1.50 ACPE Pharmacy
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 ANCC
  • 1.50 CDE
  • 1.50 Participation
Virtual Symposium: What You Need to Know About Optimizing Cardiorenal Outcomes with Novel NonSteroidal MRAs
During this recorded symposium from the 2022 American Heart Association (AHA), you will get a chance to:
Category
  • CMHC
Format
  • Video
Credits
  • 1.50 ACPE Pharmacy
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 ANCC
  • 1.50 Participation
Clinical Brief: Why Should We Use CGM in Patients With Type 2 Diabetes? Assessing the Evidence and Practical Pearls for Integration
This clinical brief was developed from a presentation at the 17th annual CMHC Annual Congress held from October 19-22, 2022 in Boston, MA. The session, “Why Should We Use CGM in Patients With Type 2 Diabetes?
Category
  • CMHC
Format
  • Monograph
Credits
  • 0.50 ABIM MOC and AMA PRA Category 1 Credit™
  • 0.50 ACPE Pharmacy
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC
  • 0.50 CDE
  • 0.50 Participation
Challenging Cases in the Management of Aortic Stenosis in Women
There are significant gaps in the diagnosis, evaluation and treatment of women with aortic stenosis (AS).
Category
  • CMHC
Format
  • Self-study / Enduring
Credits
  • 1.50 ACPE Pharmacy
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 ANCC
  • 1.50 Participation
Digital Pathway - The Intersection of NASH and Cardiometabolic Diseases: Implications for Screening, Diagnosis, and Management
Non-alcoholic steatohepatitis (NASH) is a metabolic-based constellation of multiple organ pathology that overlaps with obesity, prediabetes, type 2 diabetes, and cardiovascular disease.
Category
  • CMHC
Format
  • Self-study / Enduring
Credits
  • 2.00 ABIM MOC and AMA PRA Category 1 Credit™
  • 2.00 ACPE Pharmacy
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 ANCC
  • 2.00 CDE
  • 2.00 Participation
Atopic Dermatitis Summit: Perspectives on a Global Burden of Disease
The treatment of AD is a clinical challenge on a global level. Targeted immunomodulatory agents, based on recent advances in the understanding of the disease pathophysiology, represent additional options for long-term control.
Category
  • LivDerm
  • TME
Format
  • Video
Credits
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Participation

Pages